HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.

Abstract
The impact of low-dose spironolactone (LSPL) on polycystic ovarian syndrome (PCOS)-associated cardio-renal disorder is unknown. Therefore, the present study hypothesized that LSPL would ameliorate cardio-renal disorders in experimental PCOS animals. Eight-week-old female Wistar rats were allotted into three groups. The control group received vehicle (distilled water; per os (p.o.)), the letrozole (LET)-treated group designated as PCOS group received LET (1 mg/kg; p.o.), and PCOS+LSPL received LET and LSPL (0.25 mg/kg, p.o.). The treatment was done once daily for 21 days uninterrupted. The experimental PCOS rats were characterized with insulin resistance, as well as elevated testosterone and luteinizing hormone/follicle-stimulating hormone, with a significant increase in cardiac and renal lipid profile, oxidative stress, inflammatory biomarkers (nuclear factor-κB and tumor necrosis factor-α), lactate dehydrogenase and lactate content and decrease in cardiac and renal antioxidant system (glutathione peroxidase and reduced glutathione) compared with the control rats. In addition, immunohistochemical assessment of cardiac and renal tissue showed significant expression of inflammasome and B-cell lymphoma-2 associated X-protein (BAX) in animals with PCOS. Nevertheless, these perturbations were attenuated following the administration of LSPL. Collectively, the present results suggest that LSPL attenuates PCOS-associated cardio-renal disorders by reduction of oxidative stress and BAX/inflammasome expression.
AuthorsMmenyene U Peter, Stephanie E Areloegbe, Christopher O Akintayo, Adesola A Oniyide, Ayodeji Aturamu, Kehinde S Olaniyi
JournalCanadian journal of physiology and pharmacology (Can J Physiol Pharmacol) Vol. 100 Issue 9 Pg. 890-902 (Sep 01 2022) ISSN: 1205-7541 [Electronic] Canada
PMID35771488 (Publication Type: Journal Article)
Chemical References
  • Inflammasomes
  • bcl-2-Associated X Protein
  • Spironolactone
  • Letrozole
Topics
  • Animals
  • Disease Models, Animal
  • Female
  • Humans
  • Inflammasomes
  • Letrozole (therapeutic use)
  • Polycystic Ovary Syndrome (drug therapy, metabolism)
  • Rats
  • Rats, Wistar
  • Spironolactone (pharmacology, therapeutic use)
  • bcl-2-Associated X Protein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: